The American Journal of Medicine
Volume 121, Issue 4, Supplement , Pages S3-S10 , April 2008

Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment

  • Neal L. Benowitz, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Neal L. Benowitz, MD, Division of Clinical Pharmacology and Experimental Therapeutics, University of California-San Francisco, Box 1220, San Francisco, California 94143-1220.

References 

  1. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004;
  2. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2000. MMWR Morb Mortal Wkly Rep. 2002;51:642–645
  3. Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking cessation among self-quitters. Health Psychol. 1992;11:331–334
  4. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol. 1996;36:597–613
  5. Benowitz NL. Nicotine addiction. Prim Care. 1999;26:611–631
  6. US Department of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction. Washington, DC: Office of the Surgeon General, US Dept of Health and Human Services; 1988;
  7. Edwards G, Arif A, Hodgson R. Nomenclature and classification of drug- and alcohol-related problems: a shortened version of a WHO memorandum. Br J Addict. 1982;77:3–20
  8. Benowitz NL, Jacob P. Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther. 1985;234:153–155
  9. Benowitz NL. Compensatory smoking of low-yield cigarettes. In:  Burns DM,  Shopland DR,  Benowitz N editor. Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Bethesda, MD: US National Institutes of Health, National Cancer Institute; 2001;p. 39–63
  10. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry. 1986;43:289–294
  11. Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition. Washington, DC: American Psychiatric Association; 1994;
  12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86:1119–1127
  13. Giovino GA, Henningfield JE, Tomar SL, Escobedo LG, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev. 1995;17:48–65
  14. Rigotti NA, Singer DE, Mulley AG, Thibault GE. Smoking cessation following admission to a coronary care unit. J Gen Intern Med. 1991;6:305–311
  15. Walker MS, Vidrine DJ, Gritz ER, et al. Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2370–2377
  16. Himbury S, West R. Smoking habits after laryngectomy. BMJ. 1985;291:514–515
  17. Henningfield JE, Miyasato K, Jasinski DR. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther. 1985;234:1–12
  18. DeNoble VJ, Mele PC. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berl). 2006;184:266–272
  19. Harvey DM, Yasar S, Heishman SJ, et al. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl). 2004;175:134–142
  20. Henningfield JE. Nicotine medications for smoking cessation. N Engl J Med. 1995;333:1196–1203
  21. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25:317–324
  22. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2001;70:439–446
  23. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173–177
  24. Maskos U, Molles BE, Pons S, et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature. 2005;436:103–107
  25. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029–1032
  26. Aberger K, Chitravanshi VC, Sapru HN. Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat. Brain Res. 2001;892:138–146
  27. Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and α7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol. 1999;10:675–680
  28. Hajos M, Hurst RS, Hoffmann WE, et al. The selective α7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther. 2005;312:1213–1222
  29. Brody AL. Functional brain imaging of tobacco use and dependence. J Psychiatr Res. 2006;40:404–418
  30. Nestler EJ. Is there a common molecular pathway for addiction?. Nat Neurosci. 2005;8:1445–1449
  31. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20:92–98
  32. Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl). 1992;107:285–289
  33. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl). 2003;168:347–358
  34. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature. 1998;393:76–79
  35. Wang H, Sun X. Desensitized nicotinic receptors in brain. Brain Res Brain Res Rev. 2005;48:420–437
  36. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron. 1996;16:905–908
  37. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain α4β2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63:907–915
  38. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res. 2004;6:899–912
  39. Donny EC, Chaudhri N, Caggiula AR, et al. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (Berl). 2003;169:68–76
  40. Hughes JR. Clinical significance of tobacco withdrawal. Nicotine Tob Res. 2006;8:153–156
  41. Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52–58
  42. Rose JE, Behm FM, Levin ED. Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol Biochem Behav. 1993;44:891–900
  43. Rose JE, Behm FM, Westman EC, Johnson M. Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav. 2000;67:71–81
  44. Olausson P, Jentsch JD, Taylor JR. Repeated nicotine exposure enhances responding with conditioned reinforcement. Psychopharmacology (Berl). 2004;173:98–104
  45. Kenny PJ, Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci. 2005;25:6208–6212
  46. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human Services, Public Health Service; 2000;
  47. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med. 2008;121(4A):S20–S31
  48. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321–327
  49. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–3477
  50. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy?. Drugs. 1995;50:197–207
  51. Niaura R. Nonpharmacologic therapy for smoking cessation: characteristics and efficacy of current approaches. Am J Med. 2008;121(4A):S11–S19

 Statement of conflict of interest: Please see Author Disclosures section at the end of this article.

PII: S0002-9343(08)00103-4

doi: 10.1016/j.amjmed.2008.01.015

The American Journal of Medicine
Volume 121, Issue 4, Supplement , Pages S3-S10 , April 2008

Article Tools

* Image Usage & Resolution